Selectively replicating oncolytic adenoviruses as cancer therapeutics.
Selectively replicating oncolytic adenoviruses as cancer therapeutics.
复制标题
DOI：
--
复制
发表时间：
2002-10
影响因子：
--
通讯作者：
De-chao Yu;P. Working;D. Ando
中科院分区：
文献类型：
--
作者：
De-chao Yu;P. Working;D. Ando
在过去的十年里，人们对病毒疗法的兴趣重新抬头，导致了几种治疗人类癌症的有希望的方法。其中包括转录调控的腺病毒变体，它们优先在目标肿瘤细胞中复制并摧毁它们。到目前为止，这些溶瘤腺病毒，如CG-7060(Cell Genesys Inc)和CG-7870(Cell Genesys Inc)，已经显示出良好的安全性和显著的抗肿瘤活性。此外，当溶瘤病毒与传统的化疗或放射治疗联合使用时，也看到了协同效应。未来的临床试验需要进一步测试第一代溶瘤腺病毒的实用性。这一领域即将到来的大部分发展将围绕着提高病毒的抗肿瘤效力、调节宿主免疫反应以及最大限度地发挥溶瘤病毒与传统化疗或放射治疗的协同作用。
The resurgence of interest in virotherapy over the course of the last decade has led to several promising modalities for the treatment of human cancers. Among these are transcriptionally regulated adenovirus variants that preferentially replicate in and destroy target tumor cells. To date, these oncolytic adenoviruses, such as CG-7060 (Cell Genesys Inc) and CG-7870 (Cell Genesys Inc), have demonstrated good safety profiles and significant antitumor activity. Additionally, synergistic effects have been seen when oncolytic viruses have been used in combination with traditional chemotherapy or radiotherapy. Future clinical trials are needed to further test the utility of the first generation of oncolytic adenoviruses. Much of the upcoming development in this field will revolve around improving the antitumor efficacy of the viruses, modulating host immune responses and maximizing the synergistic effects of oncolytic viruses administered with traditional chemotherapy or radiotherapy.